header3.jpg

Our Science: IGX12

FIRST POTENTIAL mAb TREATMENT FOR INFERTILITY

Igyxos’ initial clinical candidate is IGX12, a first-in-class humanized monoclonal antibody (mAb) with a unique mechanism of action that enhances the activity of Follicle Stimulating Hormone (FSH). Evaluated in rigorous pre-clinical models, IGX12 is supported by a foundation of compelling data supporting its future advancement into the clinic. In these studies, IGX12 has been shown to:

• Increase FSH potency and efficacy in cellular signaling

• Enhance FSH potency across several in vivo female animal models 

• Boost seminal vesicle weight and spermatogenesis in male murine models

With its unique MOA for increasing FSH potency and efficacy, IGX12 has potential to be a transformational therapy in the treatment of infertility.

TARGETING UNMET FERTILITY SOLUTION NEEDS IN WOMEN AND MEN

Initial infertility treatment indications for IGX12 are in vitro fertilization (IVF) in women and hypogonadotropic hypogonadism (HH) in men. 

By boosting the efficacy and potency of FSH, IGX12 has broad potential to significantly improve IVF treatment and outcomes by increasing the success rate of ovulation, while reducing FSH injections. The treatment burden of IVF requires multiple FSH injections with a success rate of only 40 to 50 % of birth in couples after an average of four-to-five treatments. 

We are also evaluating IGX12 in the orphan indication of fertility treatment in HH, a life-altering disease characterized by the production of little or no sex hormones that can lead to little or no spermatogenesis. HH has a significant disease burden with a long duration of treatment, sometimes exceeding two years, marked by hormone injections every second or third day.

IND-ENABLING STUDIES UNDERWAY

We have commenced IND-enabling studies for IGX12 and is anticipating entering the clinic in the first quarter of 2023. In anticipation of clinical entry, we have partnered with global industry leaders for the generation of IGX12 clinical material. Our key partners include Selexis SA for cell line development and Merck KGaA and EMD Millipore and Baccinex for chemistry, manufacturing, and controls (CMC) development.